Brokerages expect Eli Lilly And Co (NYSE:LLY) to announce sales of $6.07 billion for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Eli Lilly And Co’s earnings, with estimates ranging from $6.00 billion to $6.14 billion. Eli Lilly And Co posted sales of $5.66 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 7.2%. The business is expected to announce its next earnings results on Tuesday, October 23rd.
On average, analysts expect that Eli Lilly And Co will report full year sales of $24.45 billion for the current fiscal year, with estimates ranging from $24.41 billion to $24.51 billion. For the next year, analysts forecast that the company will report sales of $25.03 billion per share, with estimates ranging from $24.89 billion to $25.12 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Eli Lilly And Co.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 24th. The company reported $1.50 EPS for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.20. The firm had revenue of $6.36 billion for the quarter, compared to analysts’ expectations of $6.05 billion. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the prior year, the business posted $1.11 earnings per share.
A number of analysts recently weighed in on the stock. Goldman Sachs Group set a $100.00 price objective on shares of Eli Lilly And Co and gave the stock a “neutral” rating in a research note on Wednesday, July 25th. Credit Suisse Group upped their price objective on shares of Eli Lilly And Co from $84.00 to $86.00 and gave the stock an “underperform” rating in a research note on Wednesday, July 25th. JPMorgan Chase & Co. set a $100.00 price objective on shares of Eli Lilly And Co and gave the stock a “buy” rating in a research note on Monday, June 11th. Berenberg Bank lowered shares of Eli Lilly And Co from a “buy” rating to a “hold” rating and set a $99.00 price objective for the company. in a research note on Wednesday, July 25th. They noted that the move was a valuation call. Finally, Barclays upped their price objective on shares of Eli Lilly And Co from $98.00 to $107.00 and gave the stock an “overweight” rating in a research note on Friday, September 7th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company’s stock. Eli Lilly And Co presently has a consensus rating of “Buy” and an average price target of $101.00.
In other news, Director Jackson P. Tai purchased 2,168 shares of the firm’s stock in a transaction on Thursday, July 26th. The stock was acquired at an average cost of $95.22 per share, with a total value of $206,436.96. Following the completion of the transaction, the director now owns 53,228 shares in the company, valued at approximately $5,068,370.16. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 185,000 shares of the stock in a transaction dated Tuesday, July 24th. The shares were sold at an average price of $92.03, for a total transaction of $17,025,550.00. Following the sale, the insider now directly owns 121,631,601 shares of the company’s stock, valued at $11,193,756,240.03. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,706,944 shares of company stock valued at $167,978,247. Insiders own 0.11% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. Mutual Advisors LLC raised its position in shares of Eli Lilly And Co by 8.4% in the 2nd quarter. Mutual Advisors LLC now owns 6,600 shares of the company’s stock valued at $563,000 after purchasing an additional 512 shares during the last quarter. HL Financial Services LLC increased its holdings in Eli Lilly And Co by 0.6% in the 2nd quarter. HL Financial Services LLC now owns 82,971 shares of the company’s stock worth $7,080,000 after buying an additional 518 shares during the period. Waverton Investment Management Ltd increased its holdings in Eli Lilly And Co by 4.4% in the 2nd quarter. Waverton Investment Management Ltd now owns 12,486 shares of the company’s stock worth $1,065,000 after buying an additional 524 shares during the period. Busey Trust CO increased its holdings in Eli Lilly And Co by 2.3% in the 2nd quarter. Busey Trust CO now owns 23,955 shares of the company’s stock worth $2,044,000 after buying an additional 545 shares during the period. Finally, Cambridge Trust Co. increased its holdings in Eli Lilly And Co by 5.1% in the 2nd quarter. Cambridge Trust Co. now owns 11,902 shares of the company’s stock worth $1,016,000 after buying an additional 578 shares during the period. 76.52% of the stock is owned by institutional investors and hedge funds.
Shares of NYSE LLY traded up $0.25 during mid-day trading on Tuesday, reaching $106.32. The company had a trading volume of 42,343 shares, compared to its average volume of 3,165,587. The company has a current ratio of 1.40, a quick ratio of 1.09 and a debt-to-equity ratio of 0.79. The stock has a market cap of $113.56 billion, a PE ratio of 24.81, a PEG ratio of 1.86 and a beta of 0.28. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $107.84.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: What does relative strength index mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.